En Es
Categories

Industry News

Companies with Lab-Developed Tests Raise USD 2 Billion

By Labmedica International staff writers
11 Oct 2017

Image: Companies with laboratory-developed tests are attracting increasing investor interest and raised over USD 2 billion between January and August 2017 (Photo courtesy of iStock).Companies with laboratory-developed tests (LTDs), tests performed by laboratories owned by IVD companies and others, are attracting increasing investor interest and raised over USD 2 billion between January and August 2017. These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

LDTs, also called as "home-brew tests" or "in-house tests" were historically low-volume, simple and well-characterized tests for low-risk diagnostic applications. However, in recent years, there has been increased focus and attention on the emergence and growing use of complex LDTs based on technologies such as polymerase chain reaction (PCR), microarrays, next generation sequencing, or other complex technology. High-risk, complex tests have now been developed as LDTs in order to provide clinical results to physicians and their patients.

Presently, LDTs are being used for complex testing which smaller laboratories are not equipped or do not choose to handle and are used for a variety of medical conditions. There are all types of LDTs, including histology and molecular testing to immunoassays; or equipment-intensive testing such as mass spectrometry or flow cytometry. The largest segments of the LDTs market are oncology, genetic (inherited) disorders, and infectious disease, although these tests can be developed and used for virtually all types of disorders.

The significant activity in the development of new LDTs, increasing revenues from current LDTs, and the large addressable markets for several emerging LDTs has attracted the interest of investors as well as of other companies looking for acquisitions. For instance, in 2016, the companies included in Kalorama’s report raised over USD 750 million, although this amount was much smaller in comparison to the over USD 2 billion raised between January and August 2017.

The LDTs market has also witnessed a significant number of acquisitions in recent years, with the major companies making several acquisitions to achieve their current market positions, while smaller clinical laboratories have also been making acquisitions. A number of new companies also continue to be founded, thus providing a continuous stream of smaller companies trying to achieve growth, which may come through acquisitions or they may end up being acquired. Hence, consolidation among companies and laboratories offering LDTs is expected to continue in the future.

Related Links:
Kalorama Information



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

12 Dec 2017
TeraRecon to Sell EnvoyAI Platform
TeraRecon, a provider of advanced visualization solutions, has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform. The platform includes a content-rich artificial intelligence (AI) marketplace, called the EnvoyAI Exchange, as well as a suite of market-ready AI-enablement technologies aimed at fostering broader access and clinical use of medical imaging algorithms within busy radiology practices.
Read More
12 Dec 2017
Google Releases AI Tool for Precision Medicine
Google LLC has announced the open source release of DeepVariant, a deep learning technology to reconstruct the true genome sequence from high-throughput sequencing (HTS) data with significantly greater accuracy than previous classical methods. DeepVariant, which was developed after more than two years of research by the Google Brain team, in collaboration with Verily Life Sciences, transforms the task of variant calling, as this reconstruction problem is known in genomics, into an image classification problem well-suited to Google's existing technology and expertise. Within a year of its development, the deep learning model had won the 2016 PrecisionFDA Truth Challenge award for Highest SNP Performance, outperforming state-of-the-art methods. Since then, the Google Brain team has reduced the error rate by over 50%.
Read More
11 Dec 2017
Esaote to Be Acquired by Consortium of Chinese Healthcare Companies
Esaote S.p.A. has entered into definitive agreements with a consortium of Chinese investors who will acquire the entire share capital of the company. The consortium acquiring Esaote comprises leading medical technology and healthcare companies, as well as financial investors with significant experience in the healthcare sector.
Read More
06 Dec 2017
Global Hybrid OR Market to Reach USD 1,17 Million by 2022
The global hybrid operating room (OR) market is expected to grow at a CAGR of 12.5% from USD 652.0 million in 2017 to USD 1,174.9 million by 2022, driven by technological advancements in robot-assisted surgeries, increasing minimally invasive surgeries, and growing patient preference for affordable & effective surgical treatments. However, high establishment costs and procedural risks for patients associated with hybrid ORs are expected to limit the market growth during 2017 to 2022.
Read More
06 Dec 2017
Siemens to List Siemens Healthineers on Frankfurt Stock Exchange
Siemens AG, a provider of medical imaging and laboratory diagnostics equipment, is preparing to list its separately managed healthcare unit, Siemens Healthineers, on the Prime Standard segment of the Frankfurt Stock Exchange's Regulated Market. The move was approved at a meeting by the company's Supervisory Board and has been planned for the first half of 2018. Siemens Healthineers AG will be established for the public listing.
Read More
06 Dec 2017
GE Healthcare and Nuance Partner with NVIDIA to Bring AI to Medical Imaging
Healthcare-solution providers GE Healthcare and Nuance Communications, Inc., have partnered with NVIDIA, a leader in visual computing technologies, for using the company’s deep learning platform to bring Artificial Intelligence (AI) to medical imaging.
Read More
06 Dec 2017
Neuroimaging Platform Uses 3D AI to Offer Brain Visualization
QMENTA, a medical image storage, processing and visualization company focused on brain data analysis, specifically using MRI and related clinical data, has developed a cloud-based system for neuroimages and all related data, with data management, analysis and visualization capabilities.
Read More
05 Dec 2017
GE Launches Drawbridge Health to Transform Blood Collection
GE Healthcare has introduced Drawbridge Health, a privately held healthcare technology company, which is developing a people-friendly system to integrate draw, collection and stabilize blood samples into a single device. The technology which integrates engineering and proprietary chemistries is also being developed to support room temperature shipping and streamlined downstream processing, thus ensuring reliable, accurate results.
Read More
29 Nov 2017
CE Mark Awarded to First Commercial Head And Neck Deep Learning Solution
The world's first commercial head and neck deep learning medical imaging solution from Aidoc, an AI startup utilizing deep learning to augment radiologists' workflow and highlight anomalous cases, has received CE (Conformité Européenne) marking, allowing for its widespread commercialization in Europe.
Read More
Copyright © 2000-2017 TradeMed.com. All rights reserved. | Terms And Conditions